Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Intellia Therapeutics 2024
Volgen
Nog geen beste keuze geweest..
Rick96 schreef op 16 april 2024 15:48 :
Nog geen beste keuze geweest..
Door de oorlog zijn de meeste koersen gedaald. Ik zit LT
Intellia Therapeutics, Inc. April 29, 2024 7:30 AM EDT Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024 Extended follow-up will include safety, kallikrein reduction and attack rate data, including number of patients who continue to be completely attack free through the latest follow-up Intellia to host investor webcast on Monday, June 3, at 8 a.m. ET CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the acceptance of an oral presentation from the Phase 1 portion of the ongoing NTLA-2002 Phase 1/2 study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024, taking place May 31 – June 3 in Valencia, Spain. NTLA-2002 is an investigational in vivo CRISPR-based gene editing therapy in development as a single-dose treatment for hereditary angioedema (HAE), a rare genetic condition that leads to potentially life-threatening swelling attacks. The presentation will include updated safety and efficacy results from the Phase 1 study across all three dose cohorts (25 mg, 50 mg and 75 mg). Presentation Details Title: CRISPR-based gene editing of KLKB1 resulted in long-term plasma kallikrein protein reduction and decreased attack rate in patients with hereditary angioedema: Updated results from a phase 1 study Session: Breakthroughs in management of Hereditary Angioedema Date and Time: Sunday, June 2, 2024, from 8:30 – 10:00 a.m. CET Presenter: Hilary Longhurst, M.D., Ph.D., FRCP, FRCPath, Senior Medical Officer at Auckland District Health Board and Honorary Associate Professor at University of Auckland, New Zealand, the trial’s principal investigator in New Zealand
HAE arts en HAE patiënt over genezing van HAE (resultaten clinical trial van Intellia ntla-2002, phase 1/2)www.rarediseaseadvisor.com/features/g...
Company update & financial results Q1/2024ir.intelliatx.com/news-releases/news-...
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Indices
AEX
912,98
-0,03%
EUR/USD
1,0859
-0,10%
FTSE 100
8.431,83
+0,14%
Germany40^
18.782,30
+0,42%
Gold spot
2.420,03
+0,20%
NY-Nasdaq Composite
16.685,97
-0,07%
Stijgers
Dalers